MX2010008816A - Metodo para tratar el cancer de prostata con el antagonista de gnrh degarelix. - Google Patents

Metodo para tratar el cancer de prostata con el antagonista de gnrh degarelix.

Info

Publication number
MX2010008816A
MX2010008816A MX2010008816A MX2010008816A MX2010008816A MX 2010008816 A MX2010008816 A MX 2010008816A MX 2010008816 A MX2010008816 A MX 2010008816A MX 2010008816 A MX2010008816 A MX 2010008816A MX 2010008816 A MX2010008816 A MX 2010008816A
Authority
MX
Mexico
Prior art keywords
prostate cancer
treating prostate
gnrh antagonist
gnrh
side effect
Prior art date
Application number
MX2010008816A
Other languages
English (en)
Spanish (es)
Inventor
Bo-Eric Persson
Tine Kold Olesen
Per Cantor
Meulen Egbert A Van Der
Jens-Kristian Slott Jensen
Original Assignee
Ferring Int Ct Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39718285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010008816(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Int Ct Sa filed Critical Ferring Int Ct Sa
Publication of MX2010008816A publication Critical patent/MX2010008816A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
MX2010008816A 2008-02-11 2009-02-10 Metodo para tratar el cancer de prostata con el antagonista de gnrh degarelix. MX2010008816A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2774108P 2008-02-11 2008-02-11
EP08250703 2008-02-29
PCT/IB2009/000350 WO2009101530A1 (en) 2008-02-11 2009-02-10 Method of treating prostate cancer with the gnrh antagonist degarelix

Publications (1)

Publication Number Publication Date
MX2010008816A true MX2010008816A (es) 2010-09-07

Family

ID=39718285

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010008816A MX2010008816A (es) 2008-02-11 2009-02-10 Metodo para tratar el cancer de prostata con el antagonista de gnrh degarelix.
MX2010008817A MX2010008817A (es) 2008-02-11 2009-02-10 Tratamiento de cancer de prostata en etapa metastatica con degarelix.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2010008817A MX2010008817A (es) 2008-02-11 2009-02-10 Tratamiento de cancer de prostata en etapa metastatica con degarelix.

Country Status (25)

Country Link
US (18) US20090203623A1 (enExample)
EP (7) EP2505204B1 (enExample)
JP (12) JP5924866B2 (enExample)
KR (8) KR20140130757A (enExample)
CN (4) CN101939020B (enExample)
AU (2) AU2009213748B9 (enExample)
BR (2) BRPI0908129A2 (enExample)
CA (3) CA2714444A1 (enExample)
CY (3) CY1115561T1 (enExample)
DK (3) DK2505204T3 (enExample)
EA (4) EA036695B1 (enExample)
ES (3) ES2540235T3 (enExample)
HK (1) HK1198243A1 (enExample)
HR (3) HRP20140665T1 (enExample)
IL (3) IL207295A (enExample)
JO (1) JOP20090061B1 (enExample)
MX (2) MX2010008816A (enExample)
NZ (4) NZ603958A (enExample)
PL (3) PL2650012T3 (enExample)
PT (3) PT2505204E (enExample)
RU (2) RU2504393C2 (enExample)
SI (3) SI2249859T1 (enExample)
TW (2) TWI442932B (enExample)
WO (2) WO2009101533A1 (enExample)
ZA (1) ZA201005697B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
JO3525B1 (ar) * 2008-02-11 2020-07-05 Ferring Int Center Sa علاج سرطان البروستاتا في المرحلة النقيلية بدواء ديجاريليكس
KR101795643B1 (ko) * 2009-05-01 2017-11-09 훼링 비.브이. 전립선암 치료용 조성물
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
FR2964323B1 (fr) * 2010-09-08 2012-11-09 Jean Pierre Raynaud Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
WO2012055903A1 (en) 2010-10-27 2012-05-03 Ferring B.V. Process for the manufacture of degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
US10952415B2 (en) 2011-03-09 2021-03-23 Richard G. Pestell Prostate cancer cell lines, gene signatures and uses thereof
CN102204889B (zh) * 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
HK1209673A1 (en) 2012-05-14 2016-04-08 Prostagene Llc Using modulators of ccr5 for treating cancer
KR102140982B1 (ko) 2012-06-01 2020-08-05 훼링 비.브이. 데가렐릭스의 제조 방법
WO2014052237A1 (en) 2012-09-26 2014-04-03 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
SMT202200255T1 (it) 2012-09-28 2022-07-21 Takeda Pharmaceuticals Co Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea
EP4223298A3 (en) 2013-03-15 2023-08-16 AbbVie Inc. Compositions for use in treating heavy menstrual bleeding
WO2014186608A1 (en) * 2013-05-15 2014-11-20 Adverse Events, Inc. System and method for surveillance and evaluation of safety risks associated with medical interventions
AU2015308987B2 (en) * 2014-08-26 2021-02-18 Kaass Discovery As Methods, agents and compositions for treatment of inflammatory conditions
JP6941565B2 (ja) 2015-05-12 2021-09-29 ドレクセル ユニバーシティ がん転移を処置または防止するのに有用な化合物および組成物、ならびにこれらの使用法
SI3518932T1 (sl) 2016-09-30 2025-03-31 Takeda Pharmaceutical Company Limited Zdravljenje raka prostate
JP6990717B2 (ja) * 2017-01-30 2022-02-03 アンテヴ リミテッド 少なくとも１種のｇｎｒｈアンタゴニストを含む組成物
KR20240096623A (ko) 2017-10-16 2024-06-26 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
US11690854B2 (en) 2018-04-19 2023-07-04 Abbvie Inc. Methods of treating heavy menstrual bleeding
CA3107597A1 (en) * 2018-08-01 2020-02-06 Abbvie Inc. Dosing regimens for elagolix
RU2731002C1 (ru) * 2019-10-22 2020-08-26 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения рака предстательной железы
CN116407494B (zh) * 2023-03-02 2024-07-09 山东大学齐鲁医院 一种醋酸地加瑞克注射液及其制备方法、用途

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
ZA735680B (en) * 1972-09-21 1974-07-31 Hoffmann La Roche Polypeptides
US4072668A (en) 1973-11-06 1978-02-07 The Salk Institute For Biological Studies LH-RH Analogs
DE2862341D1 (en) 1977-12-26 1983-11-24 Ihara Chemical Ind Co Process for producing aromatic monocarboxylic acid
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
ATE144538T1 (de) 1991-04-25 1996-11-15 Romano Deghenghi Lhrh-antagonisten
ES2159516T5 (es) 1992-02-12 2005-05-01 Daikyo Gomu Seiko Ltd. Un instrumento medico.
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
DE4305225A1 (de) * 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5825730A (en) 1995-03-10 1998-10-20 Kabushiki Kaisha Toshiba Mastering machine having non-repetitive runout compensation
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
US5710246A (en) 1996-03-19 1998-01-20 Abbott Laboratories Process for intermediates for the synthesis of LHRH antagonists
US5860957A (en) * 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5977302A (en) 1997-11-20 1999-11-02 Ortho-Mcneil Pharmaceutical, Inc. Liquid phase process for the preparation of GnRH peptides
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
WO2000004897A1 (en) 1998-07-20 2000-02-03 Peptech Limited Bioimplant formulation
MXPA02008870A (es) * 2000-03-14 2003-06-24 Zentaris Ag Novedosos antagonistas de lhrh, produccion de los mismos y sus uso como medicamentos.
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20020103131A1 (en) 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
CA2447695C (en) * 2001-06-01 2015-02-24 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
GB0117057D0 (en) 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070015713A1 (en) 2005-07-14 2007-01-18 Voyager Pharmaceutical Corporation Methods for treating prostate cancer
US20060234918A1 (en) * 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
SE0104463D0 (sv) 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
ME00509B (me) 2002-09-27 2011-10-10 Zentaris Gmbh Oblik za terapijsku primjenu aktivnih peptida sa dugotrajnim oslobođenjem aktivnog sastojka i postupak za njihovo dobijanje
GB0223367D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
AR042815A1 (es) * 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006069779A1 (en) 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
SG2013054218A (en) 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
TWI442932B (zh) * 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
ES2589322T3 (es) * 2008-02-11 2016-11-11 Safety Syringes, Inc. Jeringa con protector de seguridad de aguja y clip para evitar la liberación del protector durante un proceso de reconstitución
EP2421887B1 (en) 2009-04-24 2015-04-22 Polypeptide Laboratories A/S Method for the manufacture of degarelix
KR101795643B1 (ko) * 2009-05-01 2017-11-09 훼링 비.브이. 전립선암 치료용 조성물
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
IT1399892B1 (it) 2010-03-15 2013-05-09 Spi Tecno Srl Sistema per l illuminazione pubblica
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
WO2012055903A1 (en) * 2010-10-27 2012-05-03 Ferring B.V. Process for the manufacture of degarelix and its intermediates
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) * 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CN102204889B (zh) 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
EP2731607B1 (en) * 2011-07-15 2017-10-11 Ferring B.V. Method for timing a colonoscopy wherein a picosulate composition is administered
KR102140982B1 (ko) 2012-06-01 2020-08-05 훼링 비.브이. 데가렐릭스의 제조 방법

Also Published As

Publication number Publication date
US20190167755A1 (en) 2019-06-06
EP2650012A1 (en) 2013-10-16
DK2505204T3 (da) 2015-03-16
TW200938217A (en) 2009-09-16
US11826397B2 (en) 2023-11-28
SI2505204T1 (sl) 2015-04-30
JP6189234B2 (ja) 2017-08-30
EA200901075A1 (ru) 2010-04-30
US11766468B2 (en) 2023-09-26
KR20250028541A (ko) 2025-02-28
IL207295A0 (en) 2010-12-30
EP2505204A2 (en) 2012-10-03
AU2009213751B2 (en) 2014-09-25
PL2249859T3 (pl) 2014-10-31
TWI442932B (zh) 2014-07-01
RU2504393C2 (ru) 2014-01-20
ES2540235T3 (es) 2015-07-09
TWI539959B (zh) 2016-07-01
HRP20150290T1 (hr) 2015-04-10
AU2009213748A1 (en) 2009-08-20
BRPI0908127A2 (pt) 2015-08-04
US20220323538A1 (en) 2022-10-13
CN107412726A (zh) 2017-12-01
US10973870B2 (en) 2021-04-13
JP2024028869A (ja) 2024-03-05
US10729739B2 (en) 2020-08-04
CA2714445C (en) 2018-01-16
JP2014167009A (ja) 2014-09-11
HRP20150633T1 (hr) 2015-07-31
HK1198243A1 (en) 2015-03-20
RU2010133480A (ru) 2012-03-20
KR20150091543A (ko) 2015-08-11
US9579359B2 (en) 2017-02-28
US20090203623A1 (en) 2009-08-13
EP2249859A1 (en) 2010-11-17
US20140113870A1 (en) 2014-04-24
EP2799085A1 (en) 2014-11-05
DK2249859T3 (da) 2014-06-02
KR20140130757A (ko) 2014-11-11
ZA201005697B (en) 2014-01-24
JP2014141505A (ja) 2014-08-07
WO2009101530A1 (en) 2009-08-20
JP2022184898A (ja) 2022-12-13
US20220031801A1 (en) 2022-02-03
CN101939020B (zh) 2012-12-26
EA017582B1 (ru) 2013-01-30
EA020543B1 (ru) 2014-12-30
PT2249859E (pt) 2014-07-31
NZ603958A (en) 2013-03-28
AU2009213748B9 (en) 2014-05-22
BRPI0908129A2 (pt) 2015-08-04
TW200938218A (en) 2009-09-16
EA201300741A1 (ru) 2014-02-28
JP2016216455A (ja) 2016-12-22
JP6618967B2 (ja) 2019-12-11
RU2504394C2 (ru) 2014-01-20
US8841081B2 (en) 2014-09-23
PT2650012E (pt) 2015-06-30
US20260124269A1 (en) 2026-05-07
AU2009213751A1 (en) 2009-08-20
CY1115561T1 (el) 2017-01-04
JP5876652B2 (ja) 2016-03-02
JP7400029B2 (ja) 2023-12-18
CN101939020A (zh) 2011-01-05
US12514898B2 (en) 2026-01-06
US10695398B2 (en) 2020-06-30
EA026521B1 (ru) 2017-04-28
US9415085B2 (en) 2016-08-16
EP4257197A2 (en) 2023-10-11
HK1190912A1 (en) 2014-07-18
EP4257197A3 (en) 2023-11-29
JP2022133426A (ja) 2022-09-13
IL207400A (en) 2014-12-31
HK1145011A1 (en) 2011-03-25
RU2010133481A (ru) 2012-03-20
US20210128673A1 (en) 2021-05-06
PL2505204T3 (pl) 2015-05-29
US20170035833A1 (en) 2017-02-09
JP2018039814A (ja) 2018-03-15
US20220226422A1 (en) 2022-07-21
NZ603932A (en) 2014-04-30
US9877999B2 (en) 2018-01-30
AU2009213748B2 (en) 2014-03-13
CN101998861A (zh) 2011-03-30
EA200901074A1 (ru) 2010-04-30
US20130029910A1 (en) 2013-01-31
EP3360565A1 (en) 2018-08-15
EP2505204A3 (en) 2013-01-09
EA036695B1 (ru) 2020-12-09
US20200237854A1 (en) 2020-07-30
KR20230088848A (ko) 2023-06-20
CY1116341T1 (el) 2017-02-08
US12533387B2 (en) 2026-01-27
WO2009101533A1 (en) 2009-08-20
IL223124A0 (en) 2012-12-31
NZ587088A (en) 2012-12-21
HK1176552A1 (en) 2013-08-02
KR101542480B1 (ko) 2015-08-07
KR20180118830A (ko) 2018-10-31
DK2650012T3 (da) 2015-06-15
US20170290879A1 (en) 2017-10-12
ES2479441T3 (es) 2014-07-24
IL207295A (en) 2015-03-31
US20220218782A1 (en) 2022-07-14
CA3235099A1 (en) 2009-08-20
EP2249859B1 (en) 2014-04-23
PT2505204E (pt) 2015-03-26
IL207400A0 (en) 2010-12-30
US20220218783A1 (en) 2022-07-14
NZ587057A (en) 2012-12-21
EP2505204B1 (en) 2014-12-24
PL2650012T3 (pl) 2015-08-31
KR20220009504A (ko) 2022-01-24
HRP20140665T1 (hr) 2014-10-10
KR20100126362A (ko) 2010-12-01
CA2714444A1 (en) 2009-08-20
EP2650012B1 (en) 2015-03-25
JP2025160167A (ja) 2025-10-22
US20250134948A1 (en) 2025-05-01
KR20100123714A (ko) 2010-11-24
CY1116289T1 (el) 2017-02-08
CN103990107A (zh) 2014-08-20
CA2714445A1 (en) 2009-08-20
JP5924866B2 (ja) 2016-05-25
US20090203622A1 (en) 2009-08-13
EP2249858A1 (en) 2010-11-17
JP2011511785A (ja) 2011-04-14
EA201300742A1 (ru) 2014-02-28
US20240316142A1 (en) 2024-09-26
JP2016193910A (ja) 2016-11-17
SI2650012T1 (sl) 2015-06-30
US20140349935A1 (en) 2014-11-27
SI2249859T1 (sl) 2014-08-29
MX2010008817A (es) 2010-09-09
ES2532709T3 (es) 2015-03-31
JP2011511786A (ja) 2011-04-14
JP2026027448A (ja) 2026-02-18
JOP20090061B1 (ar) 2021-08-17
JP6254042B2 (ja) 2017-12-27

Similar Documents

Publication Publication Date Title
EP4257197A3 (en) Treatment of metastatic stage prostate cancer with degarelix
PH12017500930A1 (en) Hsp90 inhibitor combinations
AP2012006253A0 (en) Use of toll-like receptors and agonist for treating cancer.
GB2454118B (en) Hdac inhibitors and hormone targeted drugs for the treatment of cancer
MX352926B (es) Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
TN2010000209A1 (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
IL206932A0 (en) Devices, formulations, and methods for delivery of multiple beneficial agents
MX338561B (es) Un sistema para utilizarse en la reparacion de tejido.
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
WO2012018404A3 (en) Use of her3 binding agents in prostate treatment
CL2012003436A1 (es) Equipos de sujeción para interconectar distintos componentes de mobiliario de un sistema de mobiliario, que comprende por lo menos un dispositivo de sujecion que comprende un cuerpo en el que por lo menos se define parcialmente un primer canal, donde el priemer canal se encuentra dimensionado y configurado para recibir un primer riel alargado de un primer componente de mobiliario, un conjunto conector, y una abertura formada en el cuerpo; metodo de ensamblaje.
GB2411849B (en) Apparatus for mixing and discharging bone cement
IN2012DN02046A (enExample)
WO2010083385A3 (en) Compounds for reducing drug resistance and uses thereof
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
PL2293670T3 (pl) Kompozycje i sposoby leczenia grzybicy paznokci
EA201100882A1 (ru) Профилактическое/терапевтическое средство против рака
PH12012500955A1 (en) Drug combination with theobromine and its use in therapy
TN2011000214A1 (en) Combination of hsp90 and herceptin inhibitors
UA43973U (en) Method for treating osteoarthrosis
WO2011067189A3 (de) Cmet-inhibitoren zur behandlung der endometriose
WO2009138780A3 (en) Combination of an egfr inhibitor with an endocrine agent and treatment of breast cancer
HK1187832A (en) Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
GB0624687D0 (en) Treatment of cachexia
UA43489U (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанол гидрохлорида как средства, избирательно стимулирующего функцию пучковой зоны коры надпочечников

Legal Events

Date Code Title Description
FG Grant or registration